Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec;27(12):1083-8.
doi: 10.1097/INF.0b013e31817eeee5.

Pediatric antifungal utilization: new drugs, new trends

Priya A Prasad  1 , Susan E Coffin, Kateri H Leckerman, Thomas J Walsh, Theoklis E Zaoutis
Affiliations

Pediatric antifungal utilization: new drugs, new trends

Priya A Prasad et al. Pediatr Infect Dis J. 2008 Dec.

Abstract

Background: The frequency and severity of invasive fungal infections in immunocompromised patients has increased steadily over the last 2 decades. In response to the increased incidence and high mortality rates, novel antifungal agents have been developed to expand the breadth and effectiveness of treatment options available to clinicians. Despite these therapeutic advances, the impact of the availability of new antifungal agents on pediatric practice is unknown.

Methods: A retrospective cohort study was conducted using the Pediatric Health Information System database to describe the changes in pediatric antifungal therapy at 25 freestanding United States children's hospitals from 2000 to 2006. All pediatric inpatients who received a charge for one or more of the following agents were included in the analysis: conventional amphotericin B (AMB), lipid amphotericin B, fluconazole, itraconazole, voriconazole, flucytosine, caspofungin, and micafungin. Underlying conditions and fungal infection status were ascertained.

Results: A total of 62,842 patients received antifungal therapy, with prescriptions significantly increasing during the 7-year study period (P = 0.03). The most commonly prescribed antifungal agent was fluconazole (76%), followed by amphotericin preparations (26%). Prescription of AMB steadily decreased from 2000 to 2006 (P = 0.02). Prescription of voriconazole steadily increased during the study period and replaced AMB for the treatment of aspergillosis. The echinocandins steadily increased in prescription for treatment of fungal infections, particularly in disseminated/systemic candidiasis.

Conclusions: We found that the number of pediatric inpatients requiring antifungal therapy has increased significantly and the choice of treatment has changed dramatically with the introduction of newer antifungal agents.

PubMed Disclaimer

Conflict of interest statement

Dr. Zaoutis has received research funding from Merck. All other authors report no conflicts of interest relevant to this article.

Figures

FIGURE 2.
FIGURE 2.
Trends in antifungal therapy among 62,843 pediatric inpatients, 2000–2006.
FIGURE 3.
FIGURE 3.
A, Trends in antifungal therapy for disseminated systemic candidiasis. B, Trends in antifungal therapy for aspergillosis.
FIGURE 4.
FIGURE 4.
Trends in antifungal therapy for neonatal hospitalizations, 2000–2006.
See this image and copyright information in PMC

References

    1. Steinbach WJ, Walsh TJ. Mycoses in pediatric patients. Infect Dis Clin North Am. 2006;20:663–678. - PubMed
    1. Dvorak CC, Steinbach WJ, Brown JM, Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2005;36: 621–629. - PubMed
    1. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232–1239. - PubMed
    1. Zaoutis TE, Coffin SE, Chu JH, et al. Risk factors for mortality in children with candidemia. Pediatr Infect Dis J. 2005;24:736–739. - PubMed
    1. Zaoutis TE, Heydon K, Localio R, Walsh TJ, Feudtner C. Outcomes attributable to neonatal candidiasis. Clin Infect Dis. 2007;44:1187–1193. - PubMed

Publication types

MeSH terms

Substances